CSPC Pharmaceutical Secures FDA Clearance for SYHX2008 Octreotide Biosimilar Clinical Trials in US Market
CSPC Pharmaceutical Group (HKG: 1093) announced that the U.S. Food and Drug Administration (FDA) has...
Novartis
Novartis’ Del-Brax Meets Primary Endpoints in FSHD Biomarker Study – Potential First Disease-Modifying Therapy for Rare Muscular Dystrophy
Novartis AG (NYSE: NVS) announced that the biomarker cohort of the FORTITUDE Phase I/II clinical...
Novartis Secures Fourth China Approval for Tafinlar-Mekinist Combo in BRAF V600E-Mutated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Novartis AG (NYSE: NVS) announced that China’s National Medical Products Administration (NMPA) has granted approval...
Orionis Biosciences Secures $1.44 Billion Novartis Partnership for Molecular Glue Drug Discovery Using AI-Powered Allo-Glue Platform
Orionis Biosciences announced a multi-year strategic collaboration with global pharmaceutical leader Novartis AG (NYSE: NVS)...
Novartis’ Scemblix Demonstrates Sustained Superiority Over Standard TKIs in Chronic Myeloid Leukemia with 144-Week ASC4FIRST Data
Novartis AG (NYSE: NVS) announced compelling long-term efficacy data from the pivotal ASC4FIRST Phase III...
J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
Johnson & Johnson Innovative Medicine and Novartis China have announced significant leadership and organizational changes...
Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study
Novartis AG (NYSE: NVS) announced today new data from the PSMAddition Phase III clinical trial...
Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed
Novartis AG (NYSE: NVS) reported Q1 2026 financial results showing USD 13.1 billion in net...
Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
Novartis AG (NYSE: NVS) announced on April 27, 2026, that the European Commission (EC) has...
Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
Novartis AG (NYSE: NVS) announced that the Committee for Medicinal Products for Human Use (CHMP)...
Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg
Novartis AG (NYSE: NVS) announced that the World Health Organization (WHO) has granted pre-qualification (PQ)...
Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design
Novartis AG (NYSE: NVS) announced the voluntary withdrawal of its Type II variation application to...
China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program
The National Healthcare Security Administration (NHSA) has published the inaugural list of 31 innovative drugs...
Teva Secures FDA Approval for Prolia Biosimilar Ponlimsi, Advances Xolair Copycat Through Regulatory Channels
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has announced FDA marketing approval for Ponlimsi, its biosimilar...
Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline
Novartis AG (NYSE: NVS) announced an agreement to acquire Excellergy, Inc., a U.S.-based biotech, for...
Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push
Novartis AG (NYSE: NVS) announced at the China Development Forum (CDF) 2026 Annual Meeting that...
Novartis Acquires SNV4818 from Synnovation – USD 3 Billion Deal for Pan‑Mutant PI3Kα Inhibitor in Breast Cancer
Novartis AG (NYSE: NVS) announced a definitive agreement to acquire SNV4818, a pan‑mutant‑selective PI3Kα inhibitor,...
3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market
3SBio Inc. (HKG: 1530) announced NMPA marketing approval for its generic version of Novartis’ Revolade...
Novartis’ Cosentyx Wins FDA Pediatric Approval – Only IL-17A Inhibitor for Hidradenitis Suppurativa in Adolescents 12+
Novartis (NYSE: NVS) announced that Cosentyx (secukinumab) received U.S. FDA approval for treating pediatric patients aged...
Novartis’ Remibrutinib Wins CHMP Positive Opinion – Oral BTK Inhibitor Nears EU Approval for Chronic Urticaria
Novartis (NYSE: NVS) announced that the Committee for Medicinal Products for Human Use (CHMP) of the...